|
MechanismOpioid receptors antagonists [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date13 Apr 2006 |
纳曲酮植入剂在阿片类物质成瘾患者康复期志愿者中耐受性及药代动力学研究
[Translation] Study on the tolerability and pharmacokinetics of naltrexone implant in volunteers in the recovery period of opioid addiction
在阿片类物质成瘾患者康复期志愿者中研究纳曲酮植入剂给药后的耐受性及药动学,为Ⅱ期临床试验制定给药剂量提供依据。
[Translation] To study the tolerance and pharmacokinetics of naltrexone implants in volunteers in the recovery stage of opioid addiction and provide a basis for formulating the dosage for Phase II clinical trials.
100 Clinical Results associated with Shenzhen Civil Life Science Co., Ltd.
0 Patents (Medical) associated with Shenzhen Civil Life Science Co., Ltd.
100 Deals associated with Shenzhen Civil Life Science Co., Ltd.
100 Translational Medicine associated with Shenzhen Civil Life Science Co., Ltd.